Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

The Switch 2 rumor mill has been running on fumes since the official first look at Nintendo’s next-gen console, which is probably why we’re seeing more in the realm of pure speculation and ...

Merck is battling selling pressure, but strong analyst targets suggest upside potential. Pfizer faces a bearish trend with minimal upside, though analysts expect a moderate gain. Get two weeks of ...

The Nintendo Switch 2 price has reportedly been revealed, and if the report is accurate, the Nintendo Switch 2 is set to be far more expensive than the current Switch. It has been over two weeks ...

EA has become one of the first publishers to discuss - in broad terms - its plans for Switch 2, now Nintendo has finally lifted the lid on its next console. Speaking to investors last night ...

The first Switch was tough to get at launch. It seems like Nintendo is trying to change that for the successor. The first Switch was tough to get at launch. It seems like Nintendo is trying to ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Among the rumored Nintendo Switch 2 games are brand new and unannounced games as well as plenty of Nintendo Switch 2 ports for pre-existing Nintendo Switch games. In addition to this, there are ...

In this episode, Kauffman outlines her framework for sound decision-making in high-pressure situations. She also shares real-life stories of leaders she has coached through difficult decisions and ...

While the report does outline some steep declines, it also shines a light on the still-surging user base of the Switch, and teases the potential for Nintendo to smash a massive sales record it has ...

This helps support our journalism. Learn more. Please also consider subscribing to WIRED The Nintendo Switch 2 is still wrapped in mystery. Its recent reveal teased a few details—a larger ...

which we think factors in sufficient pressure from patent expiration and competition. Big picture: We continue to see Merck shares as undervalued, with the market’s fears about Keytruda’s long ...